In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Colin Baigent
Speaker
Colin Baigent

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Speciality : Risk Factors and Prevention

Professor Colin Baigent is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. Professor Baigent’s main scientific interests are (i) the design and conduct of large-scale randomized trials, and (ii) in the use of collaborative meta-analyses of individual patient data from randomized trials for the prevention and treatment of CVD, and for the study of adverse drug effects. He has a particular interest in the epidemiology of CVD in renal failure, and led the Study of Heart and Renal Protection (SHARP), the largest ever randomized trial in patients with moderate-to-severe chronic kidney disease (CKD), which showed that lowering LDL cholesterol significantly reduced the risk of atherosclerotic events. His group is now coordinating the EMPA KIDNEY trial of empagliflozin vs placebo in 5,000 patients with CKD.

5 presentations from this speaker

2019 ESC/EAS Guidelines on Dyslipidaemias.

Congress : ESC Congress 2019

  • Session : 2019 ESC Guidelines Overview
  • Speaker : C Baigent (Oxford,GB), A Catapano (Milan,IT)

Discussant review - THEMIS/THEMIS-PCI

Congress : ESC Congress 2019

  • Session : Hot Line Session 1
  • Speaker : C Baigent (Oxford,GB)

Stratifying risk and refining lipid-lowering treatment: an updated approach.

Congress : ESC Congress 2019

  • Session : Meet the Task Force of the 2019 ESC/EAS Guidelines on Dyslipidaemias
  • Speaker : C Baigent (Oxford,GB)

Observational studies to inform practice guidelines? .

Congress : ESC Congress 2018

  • Session : Evidence to inform practice: promising avenues and dead ends
  • Speaker : C Baigent (Oxford,GB)

Aspirin and cancer prevention: the evidence from randomised clinical trials.

Congress : ESC Congress 2014

  • Session : Atherothrombosis and cancer. Common mechanisms, common preventive strategies?
  • Speaker : C Baigent (Oxford,GB)

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are